{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:05:19Z","timestamp":1789679119380,"version":"4.0.1"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Doravirine (DOR)\u2010based antiretroviral therapy (ART) has been shown in clinical trials to be effective and well tolerated in treating HIV\u20101. The EffectiVeness of SwItChing to DORavirine\u2010based Antiretroviral Therapy (VICDOR) study characterized the use, effectiveness and impact on body weight and lipids of DOR\u2010based ART in a virologically suppressed switch population using real\u2010world data from Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>VICDOR was a multicentre, retrospective chart review study of virologically suppressed adults with HIV in Germany who switched to DOR\u2010based ART between January 2019 and February 2021. Demographic, clinical and laboratory data were collected up to 15\u2009months after the switch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of\u00a0193 individuals were included, with a median age of 49\u2009years (range\u2009=\u200921\u201378), 85.0% were male, 23.8% were obese (BMI \u226530\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) and 80.8% had at least one comorbidity. Overall, 84.5% switched to DOR\/3TC\/TDF. The most common reason for switching was to improve tolerability regarding weight gain (37.3%). Of the 161 individuals who remained on DOR and had HIV\u20101 RNA results, 99.4% remained virologically suppressed after 12\u2009months (with one individual having \u226550 to &lt;200 copies\/mL at month 12 and following visit). No virological failures occurred. Median LDL\u2010C change was \u22127.1\u2009mg\/dL (IQR\u2009=\u2009\u221223.0 to 8.0;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200989). Individuals switched to DOR\/3TC\/TDF had a median weight change of \u22120.9\u2009kg (IQR\u2009=\u2009\u22124.0 to 2.0;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200950) at month 12; for those switched to DOR\/3TC\/TDF to improve tolerability regarding weight gain, median weight change was \u22122.0\u2009kg (IQR\u2009=\u2009\u22125.0 to \u22121.0;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923) after 12\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DOR\u2010based ART is effective in maintaining virological suppression without evidence of ART\u2010related weight increase in a switch population of individuals with a high prevalence of comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70061","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:00:01Z","timestamp":1751619601000},"page":"1289-1299","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of switching to doravirine\u2010based antiretroviral therapy: A real\u2010world study in Germany"],"prefix":"10.1111","volume":"26","author":[{"given":"Christoph","family":"Wyen","sequence":"first","affiliation":[{"name":"Praxis am Ebertplatz  Cologne Germany"},{"name":"First Department of Internal Medicine University Hospital of Cologne  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8125-5392","authenticated-orcid":false,"given":"Michael","family":"Sabranski","sequence":"additional","affiliation":[{"name":"ICH Study Center  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Jonsson\u2010Oldenb\u00fcttel","sequence":"additional","affiliation":[{"name":"MVZ M\u00fcnchen am Goetheplatz  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Bogner","sequence":"additional","affiliation":[{"name":"University Hospital Munich, Medizinische Klinik und Poliklinik IV  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Knechten","sequence":"additional","affiliation":[{"name":"Laboratory Dr. Knechten Medical Center for HIV and Hepatitis  Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Esser","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Essen, University Duisburg Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazifa","family":"Qurishi","sequence":"additional","affiliation":[{"name":"Gemeinschaftspraxis Gotenring  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schellberg","sequence":"additional","affiliation":[{"name":"Novopraxis Berlin GbR  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kolobova","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann\u2010Patrick","family":"Pelz","sequence":"additional","affiliation":[{"name":"MSD Sharp &amp; Dohme GmbH  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohance O.","family":"Whiteside","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-5427","authenticated-orcid":false,"given":"Bekana K.","family":"Tadese","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen K.","family":"Rockstroh","sequence":"additional","affiliation":[{"name":"University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3340847"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90470-1"},{"key":"e_1_2_11_4_1","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2023"},{"key":"e_1_2_11_5_1","unstructured":"Deutsche AIDS\u2010Gesellschaft e.V. (DAIG).Deutsch\u2010\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV\u20101\u2010Infektion S2k\u2010Leitlinie.2021.https:\/\/register.awmf.org\/de\/leitlinien\/detail\/055-001"},{"key":"e_1_2_11_6_1","unstructured":"Janssen\u2010Cilag International NV.Summary of product characteristics 25 mg 100 mg and 200 mg Etravirine."},{"key":"e_1_2_11_7_1","unstructured":"Bristol\u2010Myers Squibb Pharma EEIG.Summary of product characteristics Efavirenz 50 mg 100 mg and 200 mg hard capsules."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0293"},{"key":"e_1_2_11_9_1","unstructured":"Boehringer Ingelheim International GmbH.Summary of product characteristics 200 mg Nevirapine."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-016-0330-z"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030218"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2190"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000616"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001525"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0147"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12294"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001071"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834884e6"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150970"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.9b00178"},{"key":"e_1_2_11_21_1","unstructured":"Merck Sharp & Dohme B.V.Summary of product characteristics Pifeltro 100 mg film\u2010coated tablets."},{"key":"e_1_2_11_22_1","unstructured":"Merck Sharp & Dohme B.V.Summary of product characteristics Delstrigo 100 mg\/300 mg\/245 mg film\u2010coated tablets."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30336-4"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002056"},{"key":"e_1_2_11_26_1","unstructured":"European AIDS Clinical Society (EACS) Guidelines 12.0.2023.https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002725"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010\u2010023\u201002075\u2010y"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003248"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae481"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0080\u20102018"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002541"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002350"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003101"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010\u2010021\u201001687\u20106"},{"key":"e_1_2_11_36_1","unstructured":"Robert Koch\u2010Institut Berlin Germany.Epidemiologische Kurzinformation des Robert Koch\u2010Instituts: HIV\/AIDS in Deutschland. Stand: Ende 2021.2022.https:\/\/www.rki.de\/DE\/Content\/InfAZ\/H\/HIVAIDS\/Eckdaten\/EckdatenDeutschland.pdf?__blob=publicationFile"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(24)00150\u20104"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.25646\/10670"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2021.04.015"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70061","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70061","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:27:27Z","timestamp":1772958447000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/hiv.70061"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70061","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"2024-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}